|
|||||
|
|
Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure |
|
| Authors: | Alexander M. Spence Mitchel S. Berger Robert B. Livingston Francis Ali-Osman Brian Griffin |
| Affiliation: | (1) Departments of Medicine (Neurology) and Pathology (Neuropathology), University of Washington School of Medicine, 98195 Seattle, Washington, USA;(2) Department of Neurological Surgery, Northwest Neuro-Oncology Research and Therapy Section, University of Washington School of Medicine, 98195 Seattle, Washington, USA;(3) Department of Medicine (Oncology), University of Washington School of Medicine, 98195 Seattle, Washington, USA;(4) Department of Radiation Oncology, University of Washington School of Medicine, 98195 Seattle, Washington, USA;(5) RG-27, Neurology, University of Washington, 98195 Seattle, WA, USA |
| Abstract: | Summary Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure. |
| Keywords: | malignant glioma glioblastoma brain tumors astrocytoma cisplatin chemotherapy |
| 本文献已被 SpringerLink 等数据库收录！ | |